{"id":"W4399933845","doi":"10.1016/s1470-2045(24)00255-9","title":"Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Izaak Walton Killam Health Centre; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Children’s Oncology Group; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Rhabdomyosarcoma; Temsirolimus; Chemotherapy; Oncology; Internal medicine; Pediatrics; Sarcoma; Discovery and development of mTOR inhibitors; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001099573,0.001202037,0.002406907,0.0004022052,0.0002567268,0.0007573143,0.0007523847,0.001414481,0.006124432],"category_scores_gemma":[0.001099108,0.0005023326,0.002273541,0.0003390117,0.0007478174,0.0009580512,0.0004372287,0.004171395,0.0008431383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006694793,"about_ca_system_score_gemma":0.001132956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001191149,"about_ca_topic_score_gemma":0.00418262,"domain_scores_codex":[0.9996755,0.0001506958,0.00002241948,0.00006681716,0.00002459656,0.00006004734],"domain_scores_gemma":[0.9994302,0.000158433,0.0001097722,0.00003156125,0.00002570702,0.0002442347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.923791,0.007133426,0.00189196,0.001180456,0.002075577,0.00009772895,0.000170997,0.001077101,0.003432404,0.0003642801,0.002772678,0.05601231],"study_design_scores_gemma":[0.9019085,0.09045843,0.003965802,0.00009721999,0.0006245987,0.0001081685,0.00005949647,0.0004916446,0.0005412831,0.0002165535,0.001508129,0.00002022642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856744,0.007552524,0.0003836756,0.0008872447,0.0004459445,0.001767304,0.001138327,0.0001254831,0.002025153],"genre_scores_gemma":[0.9822563,0.006126138,0.001614336,0.001592163,0.0003180316,0.002839769,0.002045768,0.00003313188,0.003174424],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006124432,"threshold_uncertainty_score":0.02048826,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02165002668722171,"score_gpt":0.3291325067953292,"score_spread":0.3074824801081075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}